Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADPTNASDAQ:AMPHOTCMKTS:CRLBFNASDAQ:SNDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADPTAdaptive Biotechnologies$7.61-2.1%$7.79$2.56▼$9.01$1.13B1.731.48 million shs1.68 million shsAMPHAmphastar Pharmaceuticals$24.50+0.4%$26.91$22.64▼$53.96$1.16B0.79465,082 shs296,382 shsCRLBFCresco Labs$0.84+8.3%$0.72$0.52▼$2.60$414.42M1.81657,143 shs347,913 shsSNDXSyndax Pharmaceuticals$13.70+2.1%$13.05$9.66▼$25.07$1.18B1.281.60 million shs1.66 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADPTAdaptive Biotechnologies-1.65%+13.76%+1.30%-1.02%+198.85%AMPHAmphastar Pharmaceuticals+0.91%+3.87%-14.14%-34.24%-40.62%CRLBFCresco Labs-8.71%+22.20%-1.26%-14.32%-62.44%SNDXSyndax Pharmaceuticals+0.68%+12.49%+1.82%-6.55%-36.28%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADPTAdaptive Biotechnologies3.5192 of 5 stars2.52.00.04.22.42.50.6AMPHAmphastar Pharmaceuticals4.4906 of 5 stars3.03.00.03.73.54.21.3CRLBFCresco Labs2.3994 of 5 stars3.53.00.00.02.40.01.3SNDXSyndax Pharmaceuticals3.6434 of 5 stars3.51.00.04.44.00.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADPTAdaptive Biotechnologies 3.00Buy$9.4023.52% UpsideAMPHAmphastar Pharmaceuticals 2.00Hold$43.5077.55% UpsideCRLBFCresco Labs 3.00Buy$3.00255.45% UpsideSNDXSyndax Pharmaceuticals 2.90Moderate Buy$36.20164.23% UpsideCurrent Analyst Ratings BreakdownLatest CRLBF, AMPH, SNDX, and ADPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/10/2025AMPHAmphastar PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold3/21/2025ADPTAdaptive BiotechnologiesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$8.00 ➝ $9.003/21/2025AMPHAmphastar PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$36.00 ➝ $32.003/20/2025SNDXSyndax PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$39.00 ➝ $41.003/17/2025CRLBFCresco LabsCormarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Moderate Buy3/4/2025SNDXSyndax PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$35.00 ➝ $39.003/4/2025SNDXSyndax PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $42.003/4/2025SNDXSyndax PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$51.00 ➝ $51.002/20/2025ADPTAdaptive BiotechnologiesPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$7.00 ➝ $11.002/13/2025ADPTAdaptive BiotechnologiesScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Outperform ➝ Sector Outperform$10.00 ➝ $12.002/4/2025AMPHAmphastar PharmaceuticalsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$66.00 ➝ $36.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADPTAdaptive Biotechnologies$178.96M6.32N/AN/A$1.37 per share5.55AMPHAmphastar Pharmaceuticals$731.97M1.59$3.42 per share7.17$13.35 per share1.84CRLBFCresco Labs$770.89M0.54$0.05 per share18.48$1.24 per share0.68SNDXSyndax Pharmaceuticals$23.68M49.78N/AN/A$6.53 per share2.10Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADPTAdaptive Biotechnologies-$159.49M-$1.09N/AN/AN/A-89.12%-64.65%-26.45%5/1/2025 (Estimated)AMPHAmphastar Pharmaceuticals$137.54M$3.068.177.452.1921.80%26.44%11.89%5/6/2025 (Estimated)CRLBFCresco Labs-$175.52M-$0.22N/AN/AN/A-9.15%-16.52%-4.81%5/13/2025 (Estimated)SNDXSyndax Pharmaceuticals-$209.36M-$3.73N/AN/AN/AN/A-64.34%-57.72%5/6/2025 (Estimated)Latest CRLBF, AMPH, SNDX, and ADPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025N/ACRLBFCresco Labs-$0.03N/AN/AN/AN/AN/A5/14/2025Q1 2025AMPHAmphastar Pharmaceuticals$0.66N/AN/AN/A$173.29 millionN/A5/6/2025Q1 2025SNDXSyndax Pharmaceuticals-$1.2419N/AN/AN/A$15.88 millionN/A5/1/2025Q1 2025ADPTAdaptive Biotechnologies-$0.28N/AN/AN/A$42.13 millionN/A3/14/2025Q4 2024CRLBFCresco Labs-$0.01-$0.01N/A-$0.01$172.10 million$176.00 million3/3/2025Q4 2024SNDXSyndax Pharmaceuticals-$0.31-$1.10-$0.79-$1.10$86.32 million$7.68 million2/11/2025Q4 2024ADPTAdaptive Biotechnologies-$0.27-$0.23+$0.04-$0.23$46.05 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADPTAdaptive BiotechnologiesN/AN/AN/AN/AN/AAMPHAmphastar PharmaceuticalsN/AN/AN/AN/AN/ACRLBFCresco LabsN/AN/AN/AN/AN/ASNDXSyndax PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADPTAdaptive BiotechnologiesN/A2.892.81AMPHAmphastar Pharmaceuticals0.823.432.61CRLBFCresco Labs1.801.971.39SNDXSyndax PharmaceuticalsN/A6.996.99Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADPTAdaptive Biotechnologies99.17%AMPHAmphastar Pharmaceuticals65.09%CRLBFCresco Labs0.05%SNDXSyndax PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipADPTAdaptive Biotechnologies6.20%AMPHAmphastar Pharmaceuticals27.10%CRLBFCresco LabsN/ASNDXSyndax Pharmaceuticals4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADPTAdaptive Biotechnologies790148.58 million138.43 millionOptionableAMPHAmphastar Pharmaceuticals1,62047.50 million35.05 millionOptionableCRLBFCresco Labs3,500491.02 millionN/ANot OptionableSNDXSyndax Pharmaceuticals11086.04 million81.86 millionOptionableCRLBF, AMPH, SNDX, and ADPT HeadlinesRecent News About These CompaniesNebula Research & Development LLC Buys 58,844 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 29 at 5:59 AM | marketbeat.comPropel Bio Management LLC Purchases 50,000 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 28 at 7:02 AM | marketbeat.comSyndax to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 5, 2025April 28 at 7:00 AM | globenewswire.comEversept Partners LP Sells 3,761,913 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 24, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Trading Up 3.6% - Should You Buy?April 23, 2025 | marketbeat.comAvoro Capital Advisors LLC Has $30.08 Million Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 23, 2025 | marketbeat.comJump Financial LLC Grows Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 21, 2025 | marketbeat.comAltium Capital Management LLC Makes New $4.89 Million Investment in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 20, 2025 | marketbeat.comRenaissance Technologies LLC Acquires New Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 20, 2025 | marketbeat.comWalleye Capital LLC Has $4.82 Million Stock Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 19, 2025 | marketbeat.comSyndax management to meet with BTIGApril 16, 2025 | markets.businessinsider.comSei Investments Co. Sells 35,414 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 14, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Raised to "Sell" at StockNews.comApril 12, 2025 | marketbeat.comSyndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 6.6% - Here's What HappenedApril 11, 2025 | marketbeat.comExodusPoint Capital Management LP Lowers Stake in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 11, 2025 | marketbeat.comSyndax price target lowered to $19 from $33 at BarclaysApril 10, 2025 | markets.businessinsider.comSyndax Pharmaceuticals (NASDAQ:SNDX) Hits New 12-Month Low - Here's WhyApril 9, 2025 | marketbeat.comSyndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by BrokeragesApril 8, 2025 | marketbeat.comRhenman & Partners Asset Management AB Sells 27,500 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 7, 2025 | marketbeat.comBryce Point Capital LLC Invests $417,000 in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 7, 2025 | marketbeat.comTrexquant Investment LP Boosts Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)April 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRLBF, AMPH, SNDX, and ADPT Company DescriptionsAdaptive Biotechnologies NASDAQ:ADPT$7.61 -0.16 (-2.06%) Closing price 04:00 PM EasternExtended Trading$7.09 -0.52 (-6.89%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.Amphastar Pharmaceuticals NASDAQ:AMPH$24.50 +0.09 (+0.37%) Closing price 04:00 PM EasternExtended Trading$24.70 +0.20 (+0.82%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.Cresco Labs OTCMKTS:CRLBF$0.84 +0.06 (+8.30%) As of 03:59 PM EasternCresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co. brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections and fruit-forward gummies under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. In addition, the company offers cannabis-infused edibles under the Sunnyside brand. The company was incorporated in 1990 and is headquartered in Chicago, Illinois.Syndax Pharmaceuticals NASDAQ:SNDX$13.70 +0.28 (+2.09%) Closing price 04:00 PM EasternExtended Trading$13.70 0.00 (-0.04%) As of 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Coca-Cola Company Stock Can Bubble to New Highs This Year Intel: Good Quarter, Bad Vibes, Guidance Rattles Investors Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet Domino’s Pizza Builds Leverage: Analysts Raise Price Targets 5 Mid-Cap Stocks Insiders Are Buying This Year Alphabet Rebounds After Strong Earnings and Buyback Announcement Occidental’s Hidden Gem: How OxyChem Could Boost Profits T-Mobile US: The Un-Carrier Is an Indisputable Buy on the Dip Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
